How common is Prostate cancer?

['Harim dispela pes']

Planti man i gat sik kensa bilong prostet o nogat?

Dispela sik i save kamap planti long ol man, na moa yet long ol man i gat bikpela krismas.

Lain American Cancer Society i tok, skin kensa tasol i save kamapim planti man moa long Amerika, na bihain long en, em kensa bilong prostate.

Long Amerika, wanpela long olgeta 9-pela 9-pela man bai kisim sik kensa bilong prostet.

Long 2021, ol i ting olsem 248,530 man bai kisim sik kensa bilong prostet na 34,130 bai dai long dispela sik.

Tasol em i bikpela samting long save olsem i gat rot long oraitim sik kensa bilong prostet, na sapos ol dokta i luksave kwik long dispela sik, planti man inap abrusim bagarap.

['Ol Tok Bilong Bipo']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.

Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.

Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.

Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.

Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.

Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.

['Toksave: sik']

['Dispela Web-sait i bilong skulim na givim save tasol long ol man, na i no bilong givim tok bilong helpim ol sikman o helpim ol narapela long sait bilong helt.']

['Ol i no ken yusim ol dispela tok bilong helpim ol long save long sik bilong ol, na ol man i laik kisim helpim long ol samting bilong helt, ol i mas toktok wantaim wanpela dokta.']

['Tingim, ol kompiuta i save yusim ol kompiuta long kamapim ol bekim bilong ol askim, tasol ol i no save kolim stret ol namba, olsem namba bilong ol man i gat wanpela sik.']

['Oltaim yu mas kisim tingting bilong dokta o narapela lain i gat save long helpim yu long sait bilong helt sapos yu gat sik. No ken sakim tok bilong dokta o wet long kisim tingting bilong dokta, long wanem, yu ritim sampela tok long dispela Web-sait. Sapos yu ting yu gat sik, ringim 911 o go long haus sik i stap klostu.']

['Toksave: raits bilong man i bosim']

['Digital Millennium Copyright Act bilong 1998, 17 U.S.C. § 512 (the DMCA) i tok ol papa bilong ol samting i gat rait long wokim ol samting, sapos ol i ting ol samting i stap long Intenet i brukim ol lo bilong ol long Amerika.']

['Sapos yu bilip olsem sampela samting i stap long dispela Web-sait o ol sevis bilong mipela i brukim lo bilong kopirait bilong yu, yu (o agent bilong yu) inap salim toksave long mipela na askim mipela long rausim o pasim rot bilong yu long kisim dispela samting.']

['Ol i mas salim ol toksave long rot bilong e-mail (lukim hap "Kontek" bilong lukim e-mail atres). ']

['Lo bilong DMCA i tok olsem toksave bilong yu long ol man i bin brukim lo bilong kopirait i mas i gat ol dispela tok: (1) stori long ol samting i gat kopirait long en, em ol man i tok ol i bin brukim; (2) stori long ol samting i gat kopirait na ol tok bilong helpim mipela long painim ol dispela samting; (3) ol tok bilong yu bilong salim pas long mipela, olsem atres, telefon namba, na e-meil atres; (4) tok yu bin mekim olsem yu bilip tru olsem man i gat kopirait o agent bilong em i no orait long ol samting i stap long dispela websait.']

['(5) Yu mas raitim wanpela pepa na putim han bilong yu bilong tokaut olsem ol tok bilong dispela pepa i stret na yu gat namba long mekim ol samting bilong lukautim ol rait bilong man i bin wokim ol samting.']

['Na (6) wanpela sain o sain bilong man i gat rait long wokim dispela samting o bilong wanpela man i gat namba long mekim wok bilong dispela man.']

['Sapos yu no raitim olgeta dispela tok, dispela inap mekim na ol i no stretim kwik komplen bilong yu.']

['Kontektim']

['Plis salim e-mail long mipela sapos yu gat sampela askim o tingting.']

How common is prostate cancer?

Prostate cancer is one of the most common types of cancer in men, particularly in older men.

According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.

In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.

In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.

However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.